Background: Cilostazol improves clinical endovascular therapy outcomes for femoropopliteal (FP) lesions in patients with symptomatic peripheral arterial disease, but whether it also has clinical benefits for patients after drug-eluting stent implantation remains unclear.
The Zilver PTX (Cook Medical, Bloomington, Ind) paclitaxel-eluting stent, recently developed as a selfexpandable nitinol drug-eluting stent (DES), has shown better long-term outcomes for femoropopliteal (FP) disease than have balloon angioplasty and provisional baremetal stent (BMS) implantation in clinical trials. 1, 2 However, even on using DES, the outcome of FP disease has been shown to be worse in accordance with the patient's clinical background or lesion complexity. 3, 4 For example, the randomized control trial showed 1-year primary patency of 84.4% in a trial that included patients with a mild background and lesion characteristics; however, the patency rate decreased from 63% to 50.2% in trials that targeted more severe conditions. 3, 4 Thus, the clinical results, even with using DESs for FP disease, still need improvement. Cilostazol is an oral antiplatelet multipotency agent [5] [6] [7] [8] [9] indicated for the treatment of intermittent claudication 10 and may lower restenosis or repeat revascularization after coronary intervention with BMS and DES. 11 This is mainly speculated to be the result of the drug's effect to suppress neointimal proliferation after stent implantation. 12, 13 Cilostazol also reduces restenosis and repeat revascularization after endovascular therapy (EVT) in patients with FP disease, 14 which is speculated to be derived not only from its suppressive effect against neointimal proliferation but also from its vasodilator effects from inhibiting phosphodiesterase type 3, which results in increased blood 
METHODS
Study population and definitions. This was a subanalysis of the ZEPHYR study, which was a prospective multicenter study investigating 831 FP lesions (797 limbs, 690 patients) treated with Zilver PTX implantation between July 2012 and April 2013. The details of the study protocol are described elsewhere. 3 The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of each participating hospital. Written informed consent was obtained from every participant.
To assess the effect of an additional administration of cilostazol on 1-year patency, the present study analyzed 475 lesions in 459 limbs of 399 patients who completed 1-year follow-up, without dropout or death, and maintained therapy with aspirin and thienopyridine, with or without cilostazol, during the follow-up period. Antiplatelet regimens during the follow-up period were used at the physician's discretion based on the patient's condition. The patients whose antiplatelet regimens were changed during the 1-year follow-up period were excluded from the present analysis.
End points. The primary end point was 12-month restenosis rate assessed with duplex ultrasound (DUS) imaging or follow-up angiography, with a tolerance of 62 months. Restenosis was defined as recurrence of $50% diameter stenosis or peak systolic velocity ratio >2.4 determined by angiography or DUS, respectively. The requirement of any reintervention or major amputation (defined as surgical limb excision above the ankle) #1 year was automatically included in restenosis. The secondary end point was a major adverse limb event (MALE), defined as a major amputation or any reintervention, including surgical or endovascular reintervention. The assessment of restenosis by using angiography or DUS was conducted only for the implanted stent or treated lesion in the ZEPYHR study. Target lesion revascularization (TLR) was conducted for $50% diameter stenosis within 5 mm of the target lesion or the stent after documentation of recurrent clinical symptoms.
Statistical analysis. Data are reported as means 6 standard deviations for continuous variables or as percentages for dichotomous variables, unless specified otherwise. P < .05 was considered statistically significant. When primary patency was compared between subgroups with and without cilostazol use, propensity score matching was performed to minimize the intergroup differences in baseline characteristics. The propensity score was developed using the logistic regression model with the variables of sex, age, hypertension, dyslipidemia, diabetes mellitus, regular dialysis, smoking status, coronary artery disease, cerebrovascular disease, chronic heart failure (history of hospitalization because of heart failure), Fontaine classification, history of revascularization, reference vessel diameter, lesion length, calcification, chronic total occlusion, and below-the-knee runoffs. Based on Austin's recommendation, 15 we matched the logit of the propensity score by using a caliper width equal to 0.2 standard deviation of the logit of the propensity score. The intergroup difference after matching was tested with paired analysis. The 95% confidence interval (CI) of the 1-year end point incidence rate and its intergroup difference and odds ratio was estimated by 100,000-time bootstrap resampling. Statistical analyses were performed with R 3.1.0 software (R Development Core Team, Vienna, Austria).
RESULTS
Baseline patient characteristics and comparison between patients with and without cilostazol treatment. The present study included 93 cilostazol-treated and 382 cilostazol-free cases. Of these, 71% (n ¼ 335) had diabetes mellitus, and 31% (n ¼ 149) were on dialysis. Critical limb ischemia accounted for 29% (n ¼ 137) of cases. The prevalence of de novo lesion was 76% (n ¼ 359), and 15% (n ¼ 70) of lesions were from in-stent restenosis. Of the 475 lesions, 120 had MALEs and 355 were MALE-free. Of the 355 MALE-free lesions, patency was assessed in 315 at 12 6 2 months and was not assessed in 40. Patency was assessed by the core laboratory, which reviewed angiograms in 141 of the 315 lesions (45%).
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Significance: The use of cilostazol may reduce restenosis in drug-eluting stents (DESs) placed for femoropopliteal disease. Table I reports the baseline characteristics of the study population. The background characteristics in the cilostazol-treated group were similar to those in the cilostazol-free group, except for coronary artery disease history, whose prevalence was significantly lower in the cilostazol-treated group (45% vs 59%; P ¼ .02).
Propensity score matching was performed to minimize the intergroup differences in baseline characteristics. The matching extracted 91 pairs (Fig 1) . The mean age was 72 years, and most patients (cilostazol-treated vs cilostazol-free) had hypertension (82% vs 85%), dyslipidemia (75% vs 78%), and diabetes mellitus (73% in both groups). Among these cases, de novo lesion was found in 67% vs 68%, and 18% vs 20% were treated for in-stent restenosis. A large number of patients who require regular dialysis treatment (26% vs 27%) and who have critical limb ischemia status (19% vs 24%) were included in both groups. The lesion length (17 cm) was longer, and the prevalence of lesion calcification was 66% vs 67% and chronic total occlusion was 41% vs 42% in both groups. No significant intergroup difference was found in baseline characteristics after matching in both subgroups (Table II) .
Effects of cilostazol in the 12-month restenosis rate and MALEs after DES implantation for FP lesions. The 1-year incidence rate of the study outcomes in the matched population is shown in Fig 2. The restenosis incidence was significantly lower in the cilostazol-treated group than in the cilostazol-free group (31% vs 51%; odds ratio, 0.5; 95% CI, 0.3-0.8; P ¼ .008). The 1-year MALE incidence rate was slightly but not significantly lower in the cilostazol-treated group (20% vs 30%; odds ratio, 0.6; 95% CI, 0.3-1.1; P ¼ .10). No patient underwent major amputation in either group, and TLR accounted for all of the MALEs in the current matched population. Consequently, the MALE incidence rate was equal to the rate of clinically driven TLR. In the population considered restenosis positive, 58% (95% CI, 43%-73%) of patients in the cilostazol-free group and 61% (95% CI, 43%-80%) in cilostazol-treated group underwent repeated revascularization, and no significant difference was found between the groups (P ¼ .81). No major fatal bleeding event was reported during the observational period in either group regarding safety of the triple-antiplatelet therapy.
In the baseline population before propensity matching, no significant differences were found between the cilostazol-treated group (20%; 95% CI, 13%-29%) and cilostazol-free group (26%; 95% CI, 22%-31%) in the 1-year restenosis incidence (P ¼ .10). In addition, no significant difference was found in the 1-year MALE incidence rate (P ¼ .21) between the cilostazol-treated group (33%; 95% CI, 23%-43%) and the cilostazol-free group (42%; 95% CI, 37%-47%). Although not statistically significant, a negative correlation between the propensity score and the restenosis incidence was confirmed by logistic regression analysis after adjusting with cilostazol administration (P ¼ .44 before adjusting, P ¼ .21 after adjusting).
DISCUSSION
This study showed that cilostazol could reduce adverse clinical events caused by in-stent restenosis after DES implantation for a FP lesion, which was the similar to BMS, as reported previously. 3 The Zilver PTX paclitaxel-eluting stent has been reported to achieve 1-year patency of 83% for lesions with a mean length of 6.6 cm and more than one patent vessel distal runoff, which did not include any patients with in-stent restenosis or hemodialysis. 1 Even in those with noncomplex disease, its 5-year patency rate decreased to 66.4%, 16 which should be further improved. The ZEPHYR study 3 also
showed that the primary patency in the real-world setting of Japan, which was considered more serious and more complex than in the setting of the randomized controlled trial, 1 was 63%, which could be definitely insignificant. The reasons these adverse outcomes occurred after EVT for FP lesions are speculated to be that the FP artery has unique motion characteristics, such as twisting, shrinking, and bending, compared with the other arteries, resulting in constant mechanical stress to the implanted stent, and its atherosclerotic lesion tends to be diffuse, long, and obstructed. Although, the patient background and lesion complexity were considered as severe in this study as in the original population, 3 even after propensity matching, the cilostazol-treated group showed a distinctive favorable effect of a 50% reduction against a restenosis event. Thus, even in the DES era, other options, such as pharmacologic intervention using cilostazol, would contribute in improving the clinical outcome of EVT for FP lesion. Cilostazol was likely considered to be prescribed to patients with a high-risk of restenosis from the result of logistic regression analysis between the propensity score and restenosis incidence after adjusting with cilostazol administration. Therefore, the baseline population could not produce significant differences of restenosis rates and MALEs between those with or without cilostazol because of its bias. After the propensity score-matching method, the favorable effects of cilostazol to restenosis incidence were detected more clearly as a result of bias reduction. Although cilostazol stopped being used after coronary artery stenting because its suppression effect for neointimal hyperplasia became inconspicuous by the rather potent suppression effect of DES, 17 particularly for clinical outcome, 
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Fig 2.
Clinical outcomes at 1 year in the matched population. The incidence of restenosis was significantly lower in the cilostazol-treated group than in the cilostazol-free group (31% vs 51%; P ¼ .008). The 1-year major adverse limb event (MALE) incidence rate was slightly, but not significantly, lower in the cilostazol-treated group (20% vs 30%; P ¼ .10). The range bars represent 95% confidence intervals (CIs).
pharmacologic interventions using cilostazol can still be considered in DES implantations for FP lesions. The lower incidence of restenosis in patients who were administered cilostazol probably resulted from the improvement of blood flow because of its vasodilatory effect and suppression of neointimal hyperplasia, which is attributed to its anti-inflammatory effect together with the improvement of vascular endothelial function and the inhibition of vascular smooth muscle cell proliferation. [5] [6] [7] [8] [9] The vasodilator property also contributes to the improvement of claudication symptoms, 10 which resulted in the decreased rate of MALEs in this study. Therefore, cilostazol is speculated to be a rational choice as a suppressor for claudication and neointimal hyperplasia after EVT for FP lesions. In this study, however, the factor of cilostazol treatment as a suppressor for claudication as a result of its vasodilatory effect did not influence the repeat revascularization rate statistically in the cases of which restenosis were considered positive. Thus, the overall results are speculated to strongly reflect the suppressive effects of neointimal hyperplasia derived from cilostazol. The favorable suppressive effects to the restenosis or repeat revascularization after DES implantation for FP lesion by cilostazol could be more evident if the sample size is larger, considering these conditions. Triple-antiplatelet therapy, comprising aspirin, clopidogrel, and cilostazol, was used in the cilostazol-treated group during the 1-year follow-up period and was not related to the increase of any major bleeding event, as previously reported. 11, 18 In coronary artery disease, cilostazol reduces restenosis and repeat revascularization and appears to be safe, with no significant increase in the risk of bleeding, as shown in a meta-analysis of randomized clinical trials comparing cilostazol with control therapy after coronary artery intervention. 11 Our study obtained a similar result for cilostazol administration in patients with FP disease after EVT. Triple-antiplatelet therapy was also favorable for stent thrombosis compared with the fewer antiplatelet agents used during the 1-year follow-up period in the ZEPHYR study. 3 These facts could also support the cilostazol administration for the DES implantation to the FP lesion. In contrast, tachycardia and headache are common adverse effects of cilostazol, which upset patients and lead to lower pharmacologic compliance. This study shares the limitations of the ZEPHYR study, 3 which was a prospective single-arm registry. Because antiplatelet regimens depend on the physician's discretion and on the patient's condition, how cilostazol is tolerated in this study population is unknown, and patients who could not maintain cilostazol or both aspirin and thienopyridine administration for 1 year were excluded. This might provide some bias in the analysis of this study. The excluded numbers of lesions correspond to the half number of lesions in the ZEPHYR study, and we cannot assess whether cilostazol has an effect on the primary patency or MALEs of that population because the specific medication period of each patient in whom these antiplatelet drugs were interrupted is not available. A large-scale, prospective, randomization protocol should be used to elucidate the superiority of cilostazol on the inhibition of in-stent restenosis. Because the population of this study included only Japanese, the outcomes might be different from other races.
CONCLUSIONS
Even with the use of DES, triple-antiplatelet therapy, including cilostazol, definitely reduces restenosis after stenting for an FP lesion rather than dual-antiplatelet therapy. Further investigation should be performed to estimate this theory in the real-world population with a proper method for establishing better treatment strategies for FP disease.
